Andrew Wood

Andrew Wood General Information

Biography

Mr. Andrew Wood serves as an Advisor at CoCo Therapeutics. Previously, he served as Co-Chairman at Calcico Therapeutics. He served as a Venture Partner at Advent Life Sciences. Andrew joined Advent in 2011 after 18 years of experience in the pharmaceutical industry with Eli Lilly & Co. He was initially responsible for the clinical development and registration of new molecules, principally in relation to neurological and psychiatric disorders, and subsequently managed both clinical and preclinical discovery organizations, across multiple therapeutic areas, in Europe, and in Asia. Latterly, Andrew was the leader of Eli Lilly's in-licensing and business development organization in Europe. Within this role, he was responsible for evaluating drug and technology development projects and for structuring collaborations with external partners in the biotechnology sector and in academia. Andrew retired from Eli Lilly in February 2010, when he worked as an independent consultant to the pharmaceutical and biotech sectors. He currently sits on company boards and SABs and is a member of the Wellcome Trust TechnologyTransfer Strategy Panel. Andrew graduated in Natural Sciences (Cambridge University) and Clinical Medicine (Oxford University Medical School) and spent 10 years in academic medicine before entering the pharmaceutical industry.